Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in pediatric intensive care units in France, September 2023 -January 2024 - Institut Pasteur
Pré-Publication, Document De Travail Année : 2024

Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in pediatric intensive care units in France, September 2023 -January 2024

Résumé

In September 2023, France was one of the first countries that started a national immunization campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of pediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative-design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis, and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.
Fichier principal
Vignette du fichier
Nirsevimab_effectiveness_Santé publique France_2024.03.12.pdf (576.24 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

pasteur-04501286 , version 1 (12-03-2024)
pasteur-04501286 , version 2 (11-06-2024)

Licence

Identifiants

  • HAL Id : pasteur-04501286 , version 1

Citer

Juliette Paireau, Cécile Durand, Sylvain Raimbault, Joséphine Cazaubon, Guillaume Mortamet, et al.. Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in pediatric intensive care units in France, September 2023 -January 2024. 2024. ⟨pasteur-04501286v1⟩
1442 Consultations
260 Téléchargements

Partager

More